{
    "id": 17243,
    "fullName": "ZMYM2 - FGFR1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ZMYM2-FGFR1 (also referred to as ZNF198-FGFR1) results from the fusion of ZMYM1 and FGFR1, demonstrating constitutive kinase activity, transforming ability, and activation of downstream Stat5, Pi3k and Notch signaling (PMID: 10887137, PMID: 15448205, PMID: 21527531).",
            "references": [
                {
                    "id": 4456,
                    "pubMedId": 21527531,
                    "title": "Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21527531"
                },
                {
                    "id": 4457,
                    "pubMedId": 15448205,
                    "title": "PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15448205"
                },
                {
                    "id": 6074,
                    "pubMedId": 10887137,
                    "title": "ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10887137"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7750,
        "geneSymbol": "ZMYM2",
        "terms": [
            "ZMYM2",
            "FIM",
            "MYM",
            "RAMP",
            "SCLL",
            "ZNF198"
        ]
    },
    "variant": "ZMYM2 - FGFR1",
    "createDate": "01/26/2016",
    "updateDate": "06/28/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2260,
                "geneSymbol": "FGFR1",
                "terms": [
                    "FGFR1",
                    "bFGF-R-1",
                    "BFGFR",
                    "CD331",
                    "CEK",
                    "ECCL",
                    "FGFBR",
                    "FGFR-1",
                    "FLG",
                    "FLT-2",
                    "FLT2",
                    "HBGFR",
                    "HH2",
                    "HRTFDS",
                    "KAL2",
                    "N-SAM",
                    "OGD"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 6185,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited colony growth in cells derived from patients with 8p11 myeloproliferative syndrome harboring ZMYM2-FGFR1 in culture (PMID: 22875613).",
            "molecularProfile": {
                "id": 17529,
                "profileName": "ZMYM2 - FGFR1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2226,
                "name": "myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5786,
                    "pubMedId": 22875613,
                    "title": "Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22875613"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6182,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) decreased proliferation and survival of ZMYM2-FGFR1 transformed cells in culture (PMID: 22875613).",
            "molecularProfile": {
                "id": 17529,
                "profileName": "ZMYM2 - FGFR1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5786,
                    "pubMedId": 22875613,
                    "title": "Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22875613"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17529,
            "profileName": "ZMYM2 - FGFR1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}